Bullous Systemic Lupus Erythematosus (BSLE) Workup
- Author: Hillary D Johnson-Jahangir, MD, PhD; Chief Editor: Dirk M Elston, MD more...
Bullous systemic lupus erythematosus occurs in the setting of systemic lupus erythematosus; thus, ANA test results generally are positive. Anti-dsDNA, anti-Sm, anti-Ro/SS-A, anti-La/SS-B, and anticardiolipin antibodies may also be detected.
Other laboratory abnormalities related to systemic lupus erythematosus can include low levels of complement (ie, C3, C4, CH50), anemia, leukopenia, thrombocytopenia, proteinuria or cellular casts upon urinalysis, and an elevated erythrocyte sedimentation rate. (See also Systemic Lupus Erythematosus and Lupus Nephritis.)
Laboratory findings in persons with toxic epidermal necrolysis–like lupus erythematosus vary depending on the underlying type of lupus erythematosus present.
Although the lupus erythematosus patients with erythema multiforme–like skin lesions who were originally described by Rowell and colleagues had immunologic features that included a speckled pattern of ANAs, anti-Ro/SS-A and/or La/SS-B antibodies, and a positive rheumatoid factor, these findings are not consistently observed in lupus erythematosus patients with this clinical presentation. Anticardiolipin antibodies and lupus anticoagulant have also been reported in individuals with Rowell syndrome.
Diagnosis of bullous systemic lupus erythematosus requires skin biopsy specimens for routine light microscopy (preferably from the edge of a fresh blister, including adjacent, clinically unblistered skin) and DIF microscopy (from perilesional skin).
Histologically, bullous systemic lupus erythematosus is characterized by dermoepidermal separation beneath an intact epidermis. A predominantly neutrophilic infiltrate is observed in an edematous upper dermis, either concentrated in the dermal papillae (similar to dermatitis herpetiformis) or distributed in a continuous band beneath the BMZ (similar to linear IgA bullous dermatosis).
Nuclear dust is often apparent, and a variable number of eosinophils and mononuclear cells are present within the dermal infiltrate. Basal keratinocyte vacuolization and other histologic features of cutaneous lupus erythematosus are typically absent.
DIF microscopy of perilesional skin reveals deposition of IgG (with and without IgM and IgA) and complement in a linear or granular bandlike pattern at the BMZ.
In type 1 bullous systemic lupus erythematosus, DIF of salt-split perilesional skin and/or IIF microscopy following incubation of the patient's serum with salt-split normal human skin reveals immunoglobulin deposits localized to the dermal floor of the split. Immunoblot and immunoprecipitation studies using the patient's serum can confirm that these antibodies recognize the 290- and 145-kd proteins of type VII collagen. An enzyme-linked immunosorbent assay (ELISA) test for rapid detection of anti–type VII collagen NC1 domain antibodies has also been developed.
In addition, direct immunoelectron microscopy can be used to demonstrate that the immunoglobulin deposits are codistributed with anchoring fibrils/type VII collagen within and just below the lamina densa.
Cases with negative IIF and an undetermined sublocalization of anti-BMZ antibodies (or antibodies recognizing a dermal antigen other than collagen VII) are referred to as type 2 bullous systemic lupus erythematosus. Of note, circulating antibodies to type VII collagen are less likely to be present in patients with a granular pattern of fluorescence on DIF. Bullous systemic lupus erythematosus characterized by immunoglobulin binding the epidermal roof (type 3 bullous systemic lupus erythematosus) or the roof and the dermal floor of salt-split skin has also been observed. Antigens in such patients have included bullous pemphigoid antigen 1, laminin-5, and laminin-6.
Histologic findings in toxic epidermal necrolysis–like and erythema multiforme–like lupus erythematosus lesions
The histologic features of toxic epidermal necrolysis–like lupus erythematosus consist of full-thickness epidermal necrosis and a sparse lymphocytic infiltrate in the upper dermis, as are seen in drug-induced toxic epidermal necrolysis.
Rowell syndrome is characterized by a vacuolar interface dermatitis with lymphocyte exocytosis; prominent necrotic keratinocytes in all layers of the epidermis; a mild, superficial, perivascular lymphocytic infiltrate; and dermal edema, features suggestive of erythema multiforme but also compatible with early, hyperacute cutaneous lupus erythematosus. DIF findings are usually negative.
Fujimoto W, Hamada T, Yamada J, Matsuura H, Iwatsuki K. Bullous Systemic Lupus Erythematosus as an Initial Manifestation of SLE. J Dermatol. 2005 Dec. 32(12):1021-7. [Medline].
Poojary S, Rais S. Bullous systemic lupus erythematosus with lupus nephritis: a rare case of a subepidermal bullous disorder in a child. Cutis. 2012 Jan. 89(1):17-21. [Medline].
Daneshpazhooh M, Shahdi M, Aghaeepoor M, Hasiri G, Chams C. A comparative study of antibody titers of blister fluid and serum in patients with subepidermal immunobullous diseases. Int J Dermatol. 2004 May. 43(5):348-51. [Medline].
Roustan G, Salas C, Barbadillo C, Sánchez Yus E, Mulero J, Simón A. Lupus erythematosus with an erythema multiforme-like eruption. Eur J Dermatol. 2000 Aug. 10(6):459-62. [Medline].
Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006 Feb. 5(2):160-4. [Medline].
Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus?. J Am Acad Dermatol. 2003 Apr. 48(4):525-9. [Medline].
Paradela S, Martinez-Gomez W, Fernandez-Jorge B, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus. 2007. 16(9):741-5. [Medline].
Yang S, Gao Y, Song Y, Liu J, Yang C, Liu J, et al. The study of the participation of basement membrane zone antibodies in the formation of the lupus band in systemic lupus erythematosus. Int J Dermatol. 2004 Jun. 43(6):420-7. [Medline].
Grabell DA, Matthews LA, Yancey KB, Chong BF. Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus. JAMA Dermatol. 2015 May. 151 (5):539-43. [Medline]. [Full Text].
Ishii N, Yoshida M, Hisamatsu Y, et al. Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br J Dermatol. 2004 May. 150(5):843-51. [Medline].
Chen M, Doostan A, Bandyopadhyay P, et al. The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita. Am J Pathol. 2007 Jun. 170(6):2009-18. [Medline]. [Full Text].
Woodley DT, Ram R, Doostan A, et al. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol. 2006 Jun. 126(6):1323-30. [Medline].
Chan LS, Lapiere JC, Chen M, et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol. 1999 May. 135(5):569-73. [Medline].
Chen M, Chan LS, Cai X, et al. Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol. 1997 Jan. 108(1):68-72. [Medline].
Fujii K, Fujimoto W, Ueda M, Makino E, Arata J. Detection of anti-type VII collagen antibody in Sjögren's syndrome/lupus erythematosus overlap syndrome with transient bullous systemic lupus erythematosus. Br J Dermatol. 1998 Aug. 139(2):302-6. [Medline].
Ting W, Stone MS, Racila D, Scofield RH, Sontheimer RD. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004. 13(12):941-50. [Medline].
Nasongkhla P, Pratchyapruit W, Tagami H. Bullous systemic lupus erythematosus induced by UVB: report a case. J Med Assoc Thai. 2012 Jul. 95(7):969-73. [Medline].
Lourenço DM, Gomes RC, Aikawa NE, Campos LM, Romiti R, Silva CA. Childhood-onset bullous systemic lupus erythematosus. Lupus. 2014 Nov. 23 (13):1422-5. [Medline].
Khandpur S, Das S, Singh MK. Rowell's syndrome revisited: report of two cases from India. Int J Dermatol. 2005 Jul. 44(7):545-9. [Medline].
Pandhi D, Singal A, Agarwal P. Rowell's syndrome and associated antiphospholipid syndrome. Clin Exp Dermatol. 2004 Jan. 29(1):22-4. [Medline].
Shteyngarts AR, Warner MR, Camisa C. Lupus erythematosus associated with erythema multiforme: does Rowell's syndrome exist?. J Am Acad Dermatol. 1999 May. 40(5 Pt 1):773-7. [Medline].
Zeitouni NC, Funaro D, Cloutier RA, Gagné E, Claveau J. Redefining Rowell's syndrome. Br J Dermatol. 2000 Feb. 142(2):343-6. [Medline].
Paradela S, Martínez-Gómez W, Fernández-Jorge B, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus. 2007. 16(9):741-5. [Medline].
Gammon WR, Fine JD, Forbes M, Briggaman RA. Immunofluorescence on split skin for the detection and differentiation of basement membrane zone autoantibodies. J Am Acad Dermatol. 1992 Jul. 27(1):79-87. [Medline].
Malcangi G, Brandozzi G, Giangiacomi M, Zampetti M, Danieli MG. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus. 2003. 12(1):63-6. [Medline].
Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011 Apr. 17(3):142-4. [Medline].
Hamminga EA, Vermeer MH. Bullous systemic lupus erythematosus responding to mycophenolate mofetil. Eur J Dermatol. 2010 Nov-Dec. 20(6):844-5. [Medline].
Anyanwu CO, Ang CC, Werth VP. Oral mucosal involvement in bullous lupus. Arthritis Rheum. 2013 Oct. 65 (10):2622. [Medline].